WAYNE, Pa., May 24, 2016 /PRNewswire/ -- Ryan & Maniskas, LLP is investigating potential
claims against the board of directors of XenoPort, Inc. ("XenoPort" or the "Company") (NASDAQ: XNPT) concerning possible breaches
of fiduciary duty and other violations of law related to the Company's efforts to sell the Company to Arbor Pharmaceuticals, LLC
in a transaction valued at approximately $467 million.
If you own shares of XenoPort and would like to learn more about this class action or if you wish to discuss these matters and
have any questions concerning this announcement or your rights, contact Richard A. Maniskas,
Esquire toll-free at (877) 316-3218 or to sign up online, visit: www.rmclasslaw.com/cases/xnpt. You may also email Mr. Maniskas at rmaniskas@rmclasslaw.com.
Under the terms of the agreement, shareholders of XenoPort will receive $7.03 in cash for each
share of XenoPort common stock.
Our investigation concerns possible breaches of fiduciary duty and other violations of state law by the Board of Directors of
XenoPort or not acting in the Company's shareholders' best interests in connection with the sale process.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan & Maniskas, LLP is devoted to protecting
the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide. To
learn more about the class action process, please visit: www.rmclasslaw.com.
CONTACT: Ryan & Maniskas, LLP
Richard A. Maniskas, Esquire
995 Old Eagle School Rd., Suite 311
Wayne, PA 19087
877-316-3218
www.rmclasslaw.com/cases/xnpt
rmaniskas@rmclasslaw.com
Logo - http://photos.prnewswire.com/prnh/20121112/MM11729LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ryan--maniskas-llp-announces-investigation-of-xenoport-inc-300273963.html
SOURCE Ryan & Maniskas, LLP